Prothena Corp Public (PRTA) Accumulated Depreciation & Amortization (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Accumulated Depreciation & Amortization of $184000.0 in Q1 2026, down 79.44% quarter-over-quarter from $895000.0 in Q4 2025, and down 17.49% on a YoY basis from $223000.0 in Q1 2025.
Prothena Corp Public (PRTA) Accumulated Depreciation & Amortization (2012 - 2026) Analysis & Trends
Prothena Corp Public's Accumulated Depreciation & Amortization history runs 15 years deep, the most recent figure standing at $184000.0 for Q1 2026.
- In Q1 2026, Accumulated Depreciation & Amortization fell 17.49% year-over-year to $184000.0; the TTM figure through Mar 2026 stood at $184000.0 (down 17.49% YoY), while the FY2025 annual figure was $895000.0, changed 0.22% from the prior year.
- Accumulated Depreciation & Amortization was $184000.0 for Q1 2026 at Prothena Corp Public, down from $895000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $928000.0 in Q4 2023 to a low of $182000.0 in Q1 2022.
- Historically, Accumulated Depreciation & Amortization has averaged $511588.2 across 5 years, with a median of $448000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation & Amortization tumbled 40.13% in 2022, then rose 24.73% in 2023.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $744000.0 in 2022, then grew by 24.73% to $928000.0 in 2023, then retreated by 3.77% to $893000.0 in 2024, then advanced by 0.22% to $895000.0 in 2025, then sank by 79.44% to $184000.0 in 2026.
- The last three Accumulated Depreciation & Amortization figures came in at $184000.0 (Q1 2026), $895000.0 (Q4 2025), and $677000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Prothena Corp Public | 459.74 Mn | 130.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184,000.00 |
| Mar 31, 2026 | 184,000.00 |
| Dec 31, 2025 | 895,000.00 |
| Dec 31, 2025 | 895,000.00 |
| Sep 30, 2025 | 677,000.00 |
| Sep 30, 2025 | 677,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Mar 31, 2025 | 223,000.00 |
| Mar 31, 2025 | 223,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Sep 30, 2024 | 672,000.00 |
| Jun 30, 2024 | 446,000.00 |
| Jun 30, 2024 | 446,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Dec 31, 2023 | 928,000.00 |
| Dec 31, 2023 | 928,000.00 |